表紙
市場調查報告書

罕見疾病治療藥的全球市場 (2019-2029年):稀少癌症、稀少代謝性疾病、稀少神經疾病、稀少血液疾病、稀少感染疾病

Global Rare Disease Drugs Market Forecast 2019-2029: Oncology, Metabolic Diseases, Neurologic Diseases, Haematology Diseases, Infectious Diseases, Specialty Pharmacies, Hospital Pharmacies, Retail Pharmacies

出版商 Visiongain Ltd 商品編碼 914583
出版日期 內容資訊 英文 250 Pages
商品交期: 最快1-2個工作天內
價格
罕見疾病治療藥的全球市場 (2019-2029年):稀少癌症、稀少代謝性疾病、稀少神經疾病、稀少血液疾病、稀少感染疾病 Global Rare Disease Drugs Market Forecast 2019-2029: Oncology, Metabolic Diseases, Neurologic Diseases, Haematology Diseases, Infectious Diseases, Specialty Pharmacies, Hospital Pharmacies, Retail Pharmacies
出版日期: 2019年08月01日內容資訊: 英文 250 Pages
簡介

2024年的全球罕見疾病治療藥的市場估算為2570億美元,在預測期間中預計將以11.3%的年複合成長率 (CAGR) 成長。

本報告提供全球罕見疾病治療藥的市場調查,市場定義和概要,對市場成長的各種影響因素及市場機會分析,各藥物、用途、通路、地區/主要國家趨勢與市場規模的變化與預測,藥劑開發平台趨勢,主要企業簡介等資訊彙整。

第1章 報告概要

第2章 簡介:罕見疾病

  • 所謂罕見疾病
  • 罕見疾病的特徵
  • 罕見疾病相關資料、統計
  • 課題
  • 罕見疾病的類型

第3章 罕見疾病治療藥市場分析、預測

  • 市場概要
  • 全球罕見疾病治療藥市場
  • 全球罕見疾病治療藥市場:銷售額預測
  • 市場佔有率的變化預測:各地區

第4章 罕見疾病:定性分析

  • 成長推動因素
  • 阻礙成長要素
  • 市場機會

第5章 罕見疾病治療藥市場分析、預測:各藥物

  • 市場概要
  • 市場預測
    • Revlimid
    • MabThera/Rituxan
    • Opdivo
    • Imbruvica
    • Sprycel
    • Avonex
    • Tasigna
    • Copaxone
    • Rebif
    • Gleevec
    • Velcade
    • 其他

第6章 罕見疾病治療藥市場分析、預測:各用途

  • 市場概要
  • 市場預測
    • 稀少癌症
    • 稀少代謝性疾病
    • 稀少神經疾病
    • 稀少血液疾病
    • 稀少感染疾病
    • 其他

第7章 罕見疾病治療藥市場分析、預測:各銷售管道

  • 市場概要
  • 市場預測
    • 專門藥局
    • 院內藥局
    • 零售藥局

第8章 開發平台分析

  • 創新罕見疾病治療藥的開發平台
    • 稀少癌症
    • 稀少自體免疫疾病
    • 血液相關罕見疾病
    • 稀少遺傳性疾病
    • 稀少感染疾病

第9章 主要國家市場分析、預測

  • 各地區明細
  • 地區市場預測
  • 市場佔有率的變化預測
  • 北美
    • 美國
    • 加拿大
  • 歐洲
    • 歐洲
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 韓國
  • 其他地區
    • 巴西
    • 墨西哥
    • 俄羅斯
    • 南非

第10章 主要企業

  • Hoffmann-La Roche Ltd.
  • AbbVie
  • Pfizer
  • 武田藥品工業
  • Bristol-Myers Squibb Company
  • Merck & Co., Inc.
  • Novartis AG
  • Celgene Corporation
  • Teva Pharmaceuticals
  • Sanofi S.A.

第11章 定性分析

  • SWOT分析
  • 波特的五力分析

第12章 總論

目錄
Product Code: PHA0461

The global rare disease drugs market is estimated to reach $257bn in 2024 and is expected to grow at a CAGR of 11.3% throughout the forecast period. In 2018, rare oncology diseases segment held 36% of share in the global rare disease drugs market.

How this report will benefit you

Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 250-page report you will receive 145 charts - all unavailable elsewhere.

The 250-page report provides clear detailed insight into the global rare disease drugs market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand-new report today you stay better informed and ready to act.

Report Scope

Global Rare Disease Drugs Market forecasts from 2019-2029

Revenue forecasts for the global rare disease drugs market by application from 2019-2029:

  • Rare Oncology Diseases
  • Rare Metabolic Diseases
  • Rare Neurologic Diseases
  • Rare Hematology Diseases
  • Rare Infectious Diseases
  • Other Rare Diseases

Revenue forecasts for the global rare disease drugs market by distribution channel from 2019-2029:

  • Specialty Pharmacies
  • Hospital Pharmacies
  • Retail Pharmacies

Revenue forecasts for the global rare disease drugs market by drug from 2019-2029:

  • Avonex
  • Copaxone
  • Gleevec
  • Imbruvica
  • MabThera/Rituxan
  • Opdivo
  • Rebif
  • Revlimid
  • Sprycel
  • Tasigna
  • Velcade
  • Other Drugs

Revenue forecasts for the rare disease drugs market by Regional and National Market from 2019-2029:

  • North America (US, Canada)
  • Europe (Germany, UK, France, Italy, Spain)
  • Asia-Pacific (Japan, China, India, South Korea)
  • RoW (Brazil, Mexico, South Africa, Russia)

Profiles and discussion on the leading companies in the rare disease drugs market:

  • AbbVie
  • Bristol-Myers Squibb (BMS)
  • Celgene
  • Merck & Co., Inc.
  • Novartis
  • Pfizer
  • Roche
  • Sanofi
  • Takeda
  • Teva

Rare disease drugs pipeline analysis covering rare oncology drugs, rare autoimmune disease drugs, blood-related rare disease drugs, rare genetic disease drugs and rare infectious disease drugs.

SWOT Analysis and Porter's Five Forces analysis of the global rare disease drugs market

Discussion on factors that drive and restrain the global rare disease drugs market as well as opportunities in this market.

Key Questions Answered by this Report:

  • What are the global revenue prospects for the period 2019 to 2029?
  • What are the leading national market potentials from 2019 to 2029?
  • How is the rare disease drugs market evolving?
  • What is driving and restraining the rare disease drugs market?
  • What are the market shares of each segment of the overall rare disease drugs market?
  • How will main rare disease drugs submarket segments develop over the forecast period and how much revenue will these submarkets account for in 2029?
  • How will the market shares for each rare disease drugs submarket develop from 2018 to 2029?
  • Which therapies can succeed and what revenues could they generate to 2029?
  • What will be the main commercial drivers for the market from 2018 to 2029?
  • How will market shares of prominent national markets change from 2018, and which countries will lead the market in 2029, achieving highest revenues and fastest growth?
  • How will that industry evolve between 2018 and 2029, especially in R&D?

Visiongain's study is intended for anyone requiring commercial analyses for the Global Rare Disease Drugs Market. You find data, trends and predictions.

Buy our report today Global Rare Disease Drugs Market Forecast 2019-2029: Oncology, Metabolic Diseases, Neurologic Diseases, Haematology Diseases, Infectious Diseases, Specialty Pharmacies, Hospital Pharmacies, Retail Pharmacies.

Visiongain is a trading partner with the US Federal Government.

Table of Contents

1. Report Overview

  • 1.1 Global Rare Disease Drugs Market Overview
  • 1.2 Global Rare Disease Drugs Market Segmentation
  • 1.3 Overview of Findings
  • 1.4 Structure of the Report
  • 1.5 Why You Should Read This Report
  • 1.6 Key Questions Answered by This Analytical Report
  • 1.7 Who is This Report For?
  • 1.8 Methods of the Study
  • 1.9 Frequently Asked Questions (FAQ)
  • 1.10 Associated Visiongain Reports
  • 1.11 About Visiongain

2. Introduction to Rare Diseases

  • 2.1 What Are Rare Diseases?
  • 2.2 Characteristics of Rare Diseases
  • 2.3 Rare Disease Facts and Statistics
  • 2.4 Enduring Challenges of Rare Diseases
  • 2.5 Types of Rare Diseases
    • 2.5.1 Rare Oncology Diseases
    • 2.5.2 Rare Metabolic Diseases
    • 2.5.3 Rare Neurologic Diseases
    • 2.5.4 Rare Hematology Diseases
    • 2.5.5 Rare Infectious Diseases
    • 2.5.6 Other Rare Diseases

3. Rare Diseases: World Market 2019-2029

  • 3.1 Rare Disease Drugs Market Overview, 2018
  • 3.2 The World Rare Disease Drugs Market
  • 3.3 World Rare Disease Drugs Market: Sales Forecast 2019-2029
  • 3.4 Changing Market Shares by Region 2019-2029

4. Rare Diseases: Qualitative Analysis 2019-2029

  • 4.1 Rare Disease Drugs Market: Drivers 2019-2029
    • 4.1.1 Increase in Prevalence of Rare Diseases
    • 4.1.2 High Investment in Rare Disease Drugs R&D
    • 4.1.3 Increase in Number of Product Approvals
    • 4.1.4 Growing Support of Government for Rare Diseases
  • 4.2 Rare Disease Drugs Market Restraints: 2019-2029
    • 4.2.1 Challenges in Treatment
    • 4.2.2 Challenges in Research and Development
    • 4.2.3 Stringent Government Regulations
  • 4.3 Rare Disease Drugs Market Opportunities: 2019-2029
    • 4.3.1 Progress in Diagnostics and Therapeutics
    • 4.3.2 Orphan Drug Opportunities
    • 4.3.3 IRDiRC Guidelines and Policies

5. Rare Disease Drugs Market by Drugs, 2019-2029

  • 5.1 Market Overview
  • 5.2 Market Forecast 2019-2029
    • 5.2.1 Revlimid: Market Forecast, 2019-2029
    • 5.2.2 MabThera/Rituxan: Market Forecast, 2019-2029
    • 5.2.3 Opdivo: Market Forecast, 2019-2029
    • 5.2.4 Imbruvica: Market Forecast, 2019-2029
    • 5.2.5 Sprycel: Market Forecast, 2019-2029
    • 5.2.6 Avonex: Market Forecast, 2019-2029
    • 5.2.7 Tasigna: Market Forecast, 2019-2029
    • 5.2.8 Copaxone: Market Forecast, 2019-2029
    • 5.2.9 Rebif: Market Forecast, 2019-2029
    • 5.2.10 Gleevec: Market Forecast, 2019-2029
    • 5.2.11 Velcade: Market Forecast, 2019-2029
    • 5.2.12 Other Drugs: Market Forecast, 2019-2029

6. Rare Disease Drugs Market by Applications, 2019-2029

  • 6.1 Market Overview
  • 6.2 Market Forecast 2019-2029
  • 6.3 Rare Oncology Diseases Market
  • 6.4 Rare Metabolic Diseases Market
  • 6.5 Rare Neurologic Diseases Market
  • 6.6 Rare Hematology Diseases Market
  • 6.7 Rare Infectious Diseases Market
  • 6.8 Other Rare Diseases Market

7. Rare Disease Drugs Market by Distribution Channel 2019-2029

  • 7.1 Market Overview
  • 7.2 Market Forecast 2019-2029
  • 7.3 Specialty Pharmacies
  • 7.4 Hospital Pharmacies
  • 7.5 Retail Pharmacies

8. Rare Disease Drugs Market - Pipeline Analysis 2019-2029

  • 8.1 Innovative Rare Disease Drugs Pipeline
    • 8.1.1 Rare Oncology Drugs in Development
    • 8.1.2 Rare Autoimmune Disease Drugs in Development
    • 8.1.3 Blood-related Rare Disease Drugs in Development
    • 8.1.4 Rare Genetic Disease Drugs in Development
    • 8.1.5 Rare Infectious Disease Drugs in Development

9. Leading National Markets 2019-2029

  • 9.1 Geographical Breakdown of the World Rare Disease Drugs Market
  • 9.2 Global Rare Disease Drugs Market: Regional Forecast 2019-2029
  • 9.3 How Will Regional Market Shares Change to 2029?
  • 9.4 North America Rare Disease Drugs Market, 2019-2029
    • 9.4.1 US Rare Disease Drugs Market Forecast 2019-2029
    • 9.4.2 Canada Rare Disease Drugs Market Forecast 2019-2029
  • 9.5 Europe Rare Disease Drugs Market, 2019-2029
    • 9.5.1 Europe Rare Disease Drugs Market Forecast 2019-2029
    • 9.5.2 Germany Rare Disease Drugs Market Forecast 2019-2029
    • 9.5.3 UK Rare Disease Drugs Market Forecast 2019-2029
    • 9.5.4 French Rare Disease Drugs Market Forecast 2019-2029
    • 9.5.5 Italian Rare Disease Drugs Market Forecast 2019-2029
    • 9.5.6 Spanish Rare Disease Drugs Market Forecast 2019-2029
  • 9.6 Asia-Pacific Rare Disease Drugs Market 2019-2029
    • 9.6.1 Japanese Rare Disease Drugs Market Forecast 2019-2029
    • 9.6.2 Chinese Rare Disease Drugs Market 2019-2029
    • 9.6.3 Indian Rare Disease Drugs Market 2019-2029
    • 9.6.4 South Korea Rare Disease Drugs Market Forecast 2019-2029
  • 9.7 RoW Rare Disease Drugs Market 2019-2029
    • 9.7.1 Brazilian Rare Disease Drugs Market Forecast 2019-2029
    • 9.7.2 Mexico Rare Disease Drugs Market 2019-2029
    • 9.7.3 Russia Rare Disease Drugs Market Forecast 2019-2029
    • 9.7.4 South Africa Rare Disease Drugs Market Forecast 2019-2029

10. Leading Companies in the Rare Disease Drugs Market

  • 10.1 Hoffmann-La Roche Ltd.
    • 10.1.1 Financial Overview
    • 10.1.2 Recent Developments
  • 10.2 AbbVie
    • 10.2.1 Financial Overview
    • 10.2.2 Recent Developments
  • 10.3 Pfizer
    • 10.3.1 Financial Overview
    • 10.3.2 Recent Developments
  • 10.4 Takeda Pharmaceuticals
    • 10.4.1 Financial Overview
    • 10.4.2 Recent Developments
  • 10.5 Bristol-Myers Squibb Company
    • 10.5.1 Financial Overview
    • 10.5.2 Recent Developments
  • 10.6 Merck & Co., Inc.
    • 10.6.1 Financial Overview
    • 10.6.2 Recent Developments
  • 10.7 Novartis AG
    • 10.7.1 Financial Overview
    • 10.7.2 Recent Developments
  • 10.8 Celgene Corporation
    • 10.8.1 Financial Overview
    • 10.8.2 Recent Developments
  • 10.9 Teva Pharmaceuticals
    • 10.9.1 Financial Overview
    • 10.9.2 Recent Developments
  • 10.10 Sanofi S.A.
    • 10.10.1 Financial Overview
    • 10.10.2 Recent Developments

11. Rare Disease Drugs Market, Qualitative Analysis, 2019-2029

  • 11.1 Rare Disease Drugs Market: SWOT Analysis, 2019-2029
    • 11.1.1 Strengths
      • 11.1.1.1 Promising Rare Disease Drugs R&D Pipeline
      • 11.1.1.2 Increase in Healthcare Awareness
    • 11.1.2 Increase in Number of Drug Approvals
    • 11.1.3 Weaknesses
    • 11.1.4 High Research and Development Cost
    • 11.1.5 Opportunities
    • 11.1.6 Demand from Emerging Market Continues
    • 11.1.7 Increase in Government Support
    • 11.1.8 Threats
    • 11.1.9 Uncertainty of R&D Results
    • 11.1.10 Barriers to Market Entry
  • 11.2 Rare Disease Drugs Market: Porters Five Forces Analysis, 2019-2029
    • 11.2.1 Bargaining Power of Supplier: Moderate
    • 11.2.2 Bargaining Power of Buyer: Low
    • 11.2.3 Competitive Rivalry: High
    • 11.2.4 The Threat of New Entrants: Low
    • 11.2.5 Threat of Substitutes: Low

12. Conclusion

  • Associated Visiongain Reports
  • Visiongain Report Sales Order Form
  • About Visiongain
  • Report Evaluation Form

List of Table

  • Table 2.1 List of Major Rare Oncology Diseases
  • Table 2.2 List of Metabolic Diseases
  • Table 2.3 List of Neurologic Diseases
  • Table 2.4 List of Hematology Diseases
  • Table 2.5 List of Some of the Major Other Rare Diseases
  • Table 3.1 Global Rare Disease Drugs Market Forecast Revenue ($bn), AGR (%), CAGR (%), 2019-2029
  • Table 5.1 Global Rare Disease Drugs Market Forecast by Drugs: Revenue ($bn), AGR (%), CAGR (%), 2019-2029
  • Table 5.2 Global Revlimid Market Forecast Revenue ($bn), AGR (%), CAGR (%) 2019-2029
  • Table 5.3 Global MabThera/Rituxan Market Forecast Revenue ($bn), AGR (%), CAGR (%) 2019-2029
  • Table 5.4 Global Opdivo Market Forecast Revenue ($bn), AGR (%), CAGR (%) 2019-2029
  • Table 5.5 Global Imbruvica Market Forecast Revenue ($bn), AGR (%), CAGR (%) 2019-2029
  • Table 5.6 Global Sprycel Market Forecast Revenue ($bn), AGR (%), CAGR (%) 2019-2029
  • Table 5.7 Global Avonex Market Forecast Revenue ($bn), AGR (%), CAGR (%) 2019-2029
  • Table 5.8 Global Tasigna Market Forecast Revenue ($bn), AGR (%), CAGR (%) 2019-2029
  • Table 5.9 Global Copaxone Market Forecast Revenue ($bn), AGR (%), CAGR (%) 2019-2029
  • Table 5.10 Global Rebif Market Forecast Revenue ($bn), AGR (%), CAGR (%) 2019-2029
  • Table 5.11 Global Gleevec Market Forecast Revenue ($bn), AGR (%), CAGR (%) 2019-2029
  • Table 5.12 Global Velcade Market Forecast Revenue ($bn), AGR (%), CAGR (%) 2019-2029
  • Table 5.13 Global Other Drugs Market Forecast Revenue ($bn), AGR (%), CAGR (%) 2019-2029
  • Table 6.1 Global Rare Disease Drugs Market Forecast by Application: Revenue ($bn), AGR (%), CAGR (%), 2019-2029
  • Table 6.2 Global Rare Oncology Diseases Market Forecast Revenue ($bn), AGR (%), CAGR (%) 2019-2029
  • Table 6.3 Global Rare Metabolic Diseases Market Forecast Revenue ($bn), AGR (%), CAGR (%) 2019-2029
  • Table 6.4 Global Rare Neurologic Diseases Market Forecast Revenue ($bn), AGR (%), CAGR (%) 2019-2029
  • Table 6.5 Global Hematology Diseases Market Forecast Revenue ($bn), AGR (%), CAGR (%) 2019-2029
  • Table 6.6 Global Infectious Diseases Market Forecast Revenue ($bn), AGR (%), CAGR (%) 2019-2029
  • Table 6.7 Other Rare Diseases Market Forecast Revenue ($bn), AGR (%), CAGR (%) 2019-2029
  • Table 7.1 Global Rare Disease Drugs Market Forecast by Distribution Channel: Revenue ($bn), AGR (%), CAGR (%), 2019-2029
  • Table 7.2 Global Specialty Pharmacies Market Forecast Revenue ($bn), AGR (%), CAGR (%) 2019-2029
  • Table 7.3 Global Hospital Pharmacies Market Forecast Revenue ($bn), AGR (%), CAGR (%) 2019-2029
  • Table 7.4 Global Retail Pharmacies Market Forecast Revenue ($bn), AGR (%), CAGR (%) 2019-2029
  • Table 8.1 Rare Oncology Drugs in Development, 2018
  • Table 8.2 Rare Autoimmune Disease Drugs in Development, 2018
  • Table 8.3 Blood-related Rare Disease Drugs in Development, 2018
  • Table 8.4 Rare Genetic Disease Drugs in Development, 2018
  • Table 8.5 Rare Infectious Disease Drugs in Development, 2018
  • Table 9.1 World Rare Disease Drugs Market by Region: Revenue ($bn) and Market Share (%) 2018 and 2029
  • Table 9.2 Global Rare Disease Drugs Market Forecast by Region: Revenue ($bn), AGR (%), CAGR (%), 2019-2029
  • Table 9.3 North America Rare Disease Drugs Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2019-2029
  • Table 9.4 North America Rare Disease Drugs Market by Region Forecast: Revenue ($bn), AGR (%), CAGR (%), 2019-2029
  • Table 9.5 US Rare Disease Drugs Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2019-2029
  • Table 9.6 Canada Rare Disease Drugs Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2019-2029
  • Table 9.7 Europe Rare Disease Drugs Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2019-2029
  • Table 9.8 Europe Rare Disease Drugs Market Forecast by Country: Revenue ($bn), AGR (%), CAGR (%), 2019-2029
  • Table 9.9 Germany Rare Disease Drugs Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2019-2029
  • Table 9.10 UK Rare Disease Drugs Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2019-2029
  • Table 9.11 French Rare Disease Drugs Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2019-2029
  • Table 9.12 Italian Rare Disease Drugs Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2019-2029
  • Table 9.13 Spanish Rare Disease Drugs Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2019-2029
  • Table 9.14 Asia-Pacific Rare Disease Drugs Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2019-2029
  • Table 9.15 Asia-Pacific Rare Disease Drugs Market Forecast by Country: Revenue ($bn), AGR (%), CAGR (%), 2019-2029
  • Table 9.16 Japanese Rare Disease Drugs Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2019-2029
  • Table 9.17 Chinese Rare Disease Drugs Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2019-2029
  • Table 9.18 Indian Rare Disease Drugs Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2019-2029
  • Table 9.19 South Korea Rare Disease Drugs Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2019-2029
  • Table 9.20 Brazilian Rare Disease Drugs Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2019-2029
  • Table 9.21 Mexico Rare Disease Drugs Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2019-2029
  • Table 9.22 Russia Rare Disease Drugs Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2019-2029
  • Table 9.23 South Africa Rare Disease Drugs Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2019-2029
  • Table 10.1 Overview: Hoffmann-La Roche Ltd.
  • Table 10.2 Overview: AbbVie
  • Table 10.3 Overview: Pfizer
  • Table 10.4 Overview: Takeda Pharmaceuticals
  • Table 10.5 Overview: Bristol-Myers Squibb Company
  • Table 10.6 Overview: Merck & Co., Inc
  • Table 10.7 Overview: Novartis
  • Table 10.8 Overview: Celgene Corporation
  • Table 10.9 Overview: Teva Pharmaceuticals
  • Table 10.10 Overview: Sanofi S.A.

List of Figure

  • Figure 1.1 Global Rare Disease Drugs Market Segmentation Overview, 2018
  • Figure 3.1 Global Rare Disease Drugs Market Forecast Revenue ($bn), AGR (%) 2019-2029
  • Figure 3.2 Global Rare Disease Drugs Market Forecast Share (%) by Region 2019-2029
  • Figure 4.1 Rare Disease Drugs Market: Drivers 2019-2029
  • Figure 4.2 Rare Disease Drugs Market: Restraints 2019-2029
  • Figure 4.3 Rare Disease Drugs Market: Trends 2019-2029
  • Figure 5.1 Global Rare Disease Drugs by Drugs Market Share Forecast (%) 2019-2029
  • Figure 5.2 Global Rare Disease Drugs Market Forecast by Drugs: Market Shares (%), 2018
  • Figure 5.3 Global Rare Disease Drugs Market Forecast by Drugs: Market Shares (%), 2019
  • Figure 5.4 Global Rare Disease Drugs Market Forecast by Drugs: Market Shares (%), 2024
  • Figure 5.5 Global Rare Disease Drugs Market Forecast by Drugs: Market Shares (%), 2029
  • Figure 5.6 Global Revlimid Market Forecast: Revenue ($bn) and AGR (%), 2019-2029
  • Figure 5.7 Global MabThera/Rituxan Market Forecast: Revenue ($bn) and AGR (%), 2019-2029
  • Figure 5.8 Global Opdivo Market Forecast: Revenue ($bn) and AGR (%), 2019-2029
  • Figure 5.9 Global Imbruvica Market Forecast: Revenue ($bn) and AGR (%), 2019-2029
  • Figure 5.10 Global Sprycel Market Forecast: Revenue ($bn) and AGR (%), 2019-2029
  • Figure 5.11 Global Avonex Market Forecast: Revenue ($bn) and AGR (%), 2019-2029
  • Figure 5.12 Global Tasigna Market Forecast: Revenue ($bn) and AGR (%), 2019-2029
  • Figure 5.13 Global Copaxone Market Forecast: Revenue ($bn) and AGR (%), 2019-2029
  • Figure 5.14 Global Rebif Market Forecast: Revenue ($bn) and AGR (%), 2019-2029
  • Figure 5.15 Global Gleevec Market Forecast: Revenue ($bn) and AGR (%), 2019-2029
  • Figure 5.16 Global Velcade Market Forecast: Revenue ($bn) and AGR (%), 2019-2029
  • Figure 5.17 Global Other Drugs Market Forecast: Revenue ($bn) and AGR (%), 2019-2029
  • Figure 6.1 Global Rare Disease Drugs Market Forecast by Application Market Share (%) 2019-2029
  • Figure 6.2 Global Rare Disease Drugs Market Forecast by Application: Market Shares (%), 2018
  • Figure 6.3 Global Rare Disease Drugs Market Forecast by Application: Market Shares (%), 2024
  • Figure 6.4 Global Rare Disease Drugs Market Forecast by Application: Market Shares (%), 2029
  • Figure 6.5 Global Rare Oncology Diseases Market Forecast: Revenue ($bn) and AGR (%), 2019-2029
  • Figure 6.6 Global Rare Metabolic Diseases Market Forecast: Revenue ($bn) and AGR (%), 2019-2029
  • Figure 6.7 Global Rare Neurologic Diseases Market Forecast: Revenue ($bn) and AGR (%), 2019-2029
  • Figure 6.8 Global Hematology Diseases Market Forecast: Revenue ($bn) and AGR (%), 2019-2029
  • Figure 6.9 Global Infectious Diseases Market Forecast: Revenue ($bn) and AGR (%), 2019-2029
  • Figure 6.10 Other Rare Diseases Market Forecast: Revenue ($bn) and AGR (%), 2019-2029
  • Figure 7.1 Global Rare Disease Drugs by Distribution Channel Market Share (%) 2019-2029
  • Figure 7.2 Global Rare Disease Drugs by Distribution Channel: Market Shares (%), 2018
  • Figure 7.3 Global Rare Disease Drugs by Distribution Channel: Market Shares (%), 2024
  • Figure 7.4 Global Rare Disease Drugs by Distribution Channel: Market Shares (%), 2029
  • Figure 7.5 Global Specialty Pharmacies Market Forecast: Revenue ($bn) and AGR (%), 2019-2029
  • Figure 7.6 Global Hospital Pharmacies Market Forecast: Revenue ($bn) and AGR (%), 2019-2029
  • Figure 7.7 Global Retail Pharmacies Market Forecast: Revenue ($bn) and AGR (%), 2019-2029
  • Figure 9.1 Global Rare Disease Drugs Market by Region: Revenues (%), 2018
  • Figure 9.2 Global Rare Disease Drugs Market by Region: Revenues (%), 2024
  • Figure 9.3 Global Rare Disease Drugs Market by Region: Revenues (%), 2029
  • Figure 9.4 North America Rare Disease Drugs Market Forecast: Revenue ($bn) and AGR (%), 2019-2029
  • Figure 9.5 North America Rare Disease Drugs Market by Region Forecast: Market Share 2019-2029
  • Figure 9.6 US Rare Disease Drugs Market Forecast: Revenue ($bn) and AGR (%), 2019-2029
  • Figure 9.7 Canada Rare Disease Drugs Market Forecast: Revenue ($bn) and AGR (%), 2019-2029
  • Figure 9.8 Europe Rare Disease Drugs Market Forecast: Revenue ($bn) and AGR (%), 2019-2029
  • Figure 9.9 Europe Rare Disease Drugs Market by Country: Revenue (%), 2019-2029
  • Figure 9.10 Germany Rare Disease Drugs Market Forecast: Revenue ($bn) and AGR (%), 2019-2029
  • Figure 9.11 UK Rare Disease Drugs Market Forecast: Revenue ($bn) and AGR (%), 2019-2029
  • Figure 9.12 French Rare Disease Drugs Market Forecast: Revenue ($bn) and AGR (%), 2019-2029
  • Figure 9.13 Italian Rare Disease Drugs Market Forecast: Revenue ($bn) and AGR (%), 2019-2029
  • Figure 9.14 Spanish Rare Disease Drugs Market Forecast: Revenue ($bn) and AGR (%), 2019-2029
  • Figure 9.15 Asia-Pacific Rare Disease Drugs Market Forecast: Revenue ($bn) and AGR (%), 2019-2029
  • Figure 9.16 Asia-Pacific Rare Disease Drugs Market by Country: Revenue (%), 2019-2029
  • Figure 9.17 Japanese Rare Disease Drugs Market Forecast: Revenue ($bn) and AGR (%), 2019-2029
  • Figure 9.18 Chinese Rare Disease Drugs Market Forecast: Revenue ($bn) and AGR (%), 2019-2029
  • Figure 9.19 Indian Rare Disease Drugs Market Forecast: Revenue ($bn) and AGR (%), 2019-2029
  • Figure 9.20 South Korea Rare Disease Drugs Market Forecast: Revenue ($bn) and AGR (%), 2019-2029
  • Figure 9.21 Brazilian Rare Disease Drugs Market Forecast: Revenue ($bn) and AGR (%), 2019-2029
  • Figure 9.22 Mexico Rare Disease Drugs Market Forecast: Revenue ($bn) and AGR (%), 2019-2029
  • Figure 9.23 Russia Rare Disease Drugs Market Forecast: Revenue ($bn) and AGR (%), 2019-2029
  • Figure 9.24 South Africa Rare Disease Drugs Market Forecast: Revenue ($bn) and AGR (%), 2019-2029
  • Figure 10.1 Hoffmann-La Roche Ltd.: Financial Overview, 2016-2018
  • Figure 10.2 AbbVie: Financial Overview, 2016-2018
  • Figure 10.3 Pfizer: Financial Overview: 2016-2018
  • Figure 10.4 Takeda Pharmaceuticals: Financial Overview 2016-2018
  • Figure 10.5 Bristol-Myers Squibb Company: Financial Overview 2016- 2018
  • Figure 10.6 Merck & Co., Inc: Financial Overview 2016-2018
  • Figure 10.7 Novartis: Financial Overview 2016-2018
  • Figure 10.8 Celgene Corporation: Financial Overview 2016-2018
  • Figure 10.9 Teva Pharmaceuticals: Financial Overview 2016-2018
  • Figure 10.10 Sanofi S.A.: Financial Overview 2016-2018
  • Figure 11.1 SWOT Analysis of the Global Rare Disease Drugs Market, 2019-2029
  • Figure 12.1 Global Rare Disease Drugs Market Forecast Revenue ($bn), AGR (%) 2019-2029
  • Figure 12.2 Global Rare Disease Drugs Market Forecast Share (%, By Region 2018, 2024 & 2029)

List of Companies Mentioned in the Report:

  • AB Science
  • AbbVie
  • Acceleron Pharma & Celgene
  • Acer Therapeutics
  • Actavis Generics
  • Actelion Pharmaceuticals
  • Actinium Pharmaceuticals
  • Adaptimmune
  • Aduro BioTech
  • Advanced Accelerator Applications
  • Advantagene
  • Advaxis
  • Advenchen Laboratories
  • Affimed Therapeutics & Merck
  • Agenus
  • Agios Pharmaceuticals
  • Akashi Therapeutics
  • Akcea Therapeutics
  • Alcobra
  • Alexion Pharmaceuticals
  • Alkeus Pharmaceuticals
  • Allergan
  • Alnylam Pharmaceuticals
  • Ambit Biosciences
  • AmerisourceBergen Corporation
  • Amgen
  • Amicus Therapeutics
  • Andarix Pharmaceuticals
  • Angimmune
  • Angiochem
  • AntiVirus Therapeutics
  • Applied Genetic Technologies
  • Araim Pharmaceuticals
  • Arch Biopartners
  • arGentis Pharmaceuticals
  • ARIAD Pharmaceuticals
  • ArmaGen Technologies
  • ARMGO Pharma
  • AROG Pharmaceuticals
  • ArQule
  • ArQule
  • Array BioPharma
  • Arrowhead Research
  • Astellas Pharma US
  • Astex Pharmaceuticals
  • AstraZeneca
  • ATARA Biotherapeutics
  • Atox Bio
  • aTyr Pharma
  • Baxalta
  • Bayer HealthCare Pharmaceuticals
  • Belrose Pharmaceuticals
  • BerGenBio
  • BioBlast Pharma
  • BioCryst Pharmaceuticals
  • Biodel
  • Biogen
  • BioInvent International
  • BioLineRx
  • BioMarin Pharmaceutical
  • BioNTech
  • Bio-Path Holdings
  • Biotest Pharmaceuticals
  • Blaze Bioscience
  • bluebird bio
  • Blueprint Medicines
  • Boehringer Ingelheim Pharmaceuticals
  • Bristol-Myers Squibb
  • Burzynski Research Institute
  • Caladrius Biosciences
  • Cancer Advances
  • Cancer Prevention Pharmaceutical
  • Capricor Therapeutics
  • Cardinal Health, Inc.
  • CASI Pharmaceuticals
  • Catabasis Pharmaceuticals
  • Cavion
  • Celator Pharmaceuticals
  • Celgene Corporation
  • Cell Medica
  • Cell Therapeutics
  • Cellectar Biosciences
  • CEL-SCI
  • Celsion
  • Celtaxsys
  • Cempra Pharmaceuticals
  • CerRx
  • Cerulean Pharma
  • ChemoCentryx
  • Chugai Pharma
  • Cidara Therapeutics
  • Cleave Biosciences
  • Clementia Pharmaceuticals
  • Clinuvel
  • Clovis Oncology
  • Confluence Pharmaceuticals
  • Corbus Pharmaceuticals
  • Cornerstone Pharmaceuticals
  • Cortice Biosciences
  • Critical Outcome Technologies
  • Curis
  • Cyclacel
  • CymaBay Therapeutics
  • CytRx
  • Daiichi Sankyo
  • Deciphera Pharmaceuticals
  • Delcath Systems
  • DelMar Pharmaceuticals
  • Diffusion Pharmaceuticals
  • Dimension Therapeutics
  • Diurnal
  • DNAtrix
  • Eddingpharm
  • Edimer Pharmaceuticals
  • Edison Pharmaceuticals
  • Eiger Biopharmaceuticals
  • Eisai
  • Eleison Pharmaceuticals
  • Eli Lilly
  • EMD Serono & Pfizer
  • Emergent BioSolutions
  • Emmaus Medical
  • Epitopoietic Research
  • Epizyme
  • Epizyme
  • EryDel
  • Escala Therapeutics
  • Essentialis
  • Five Prime Therapeutics
  • Fortress Biotech
  • Gamida Cell
  • Gem Pharmaceuticals
  • Gen Sight Biologics
  • Genentech
  • GenSpera
  • Genzyme
  • Gilead Sciences
  • GlaxoSmithKline
  • Gliknik
  • Global Blood Therapeutics
  • GlycoMimetics
  • Golden Biotechnology
  • Gradalis
  • Grifols Therapeutics
  • GW Pharma
  • Halozyme Therapeutics
  • Hanmi
  • Hoffmann-La Roche Ltd
  • Horizon Pharma
  • Idera Pharmaceuticals
  • Ignyta
  • Immatics Biotechnologies
  • Immune Design
  • Immune Pharmaceuticals
  • Immune Response BioPharma
  • Immune Therapeutics
  • ImmunoCellular Therapeutics
  • ImmunoGen
  • Immunomedics
  • Immunovaccine Technologies
  • Incyte
  • Infinity Pharmaceuticals
  • InnoPharma
  • Insmed
  • Insys Therapeutics
  • Ionis Pharmaceuticals
  • Ionis Pharmaceuticals
  • Ipsen Biopharmaceuticals
  • IRX Therapeutics
  • Janssen Biotech
  • jCyte
  • Juno Therapeutics
  • Karyopharm Therapeutics
  • Kevelt
  • Kyowa Kirin USA
  • LeafBio
  • Lexicon Pharmaceuticals
  • Lion Biotechnologies
  • LipimetiX Development
  • MabVax Therapeutics
  • Marathon Pharmaceuticals
  • Marina Biotech
  • Mast Therapeutics
  • McKesson Corporation
  • MedImmune
  • MEI Pharma
  • Merck & Co., Inc
  • Millendo Therapeutics
  • Millennium Pharmaceuticals
  • Milo Biotechnology
  • Minneamrita Therapeutics
  • Mirati Therapeutics
  • Momenta Pharmaceuticals
  • MorphoSys
  • Nektar Therapeutics
  • NeOnc Technologies
  • Neuren Pharmaceuticals
  • Neurolixis
  • Neurotech USA
  • NGM Biopharmaceuticals
  • NightstaRx
  • Nivalis Therapeutics
  • NKT Therapeutics
  • Novartis Pharmaceuticals
  • Novo Nordisk
  • Novoteris
  • Ocata Therapeutics
  • Omeros
  • On Target Laboratories
  • Oncolix
  • Oncolytics Biotech
  • OncoMed Pharmaceuticals
  • OncoMed Pharmaceuticals & GlaxoSmithKline
  • Onconova Therapeutics
  • OncoPep
  • Oncopeptides
  • OPKO Biologics
  • OSE Pharma
  • Otsuka Pharmaceutical
  • OXiGENE
  • Patagonia Pharmaceuticals
  • Peregrine Pharmaceuticals
  • Pfizer Inc.
  • Pharmacyclics
  • PharmaCyte Biotech
  • PharmaEssentia, Corporation
  • PharmaMar USA
  • Plexxikon
  • PNP Therapeutics
  • Polaris Pharmaceuticals
  • Polynoma
  • Prana Biotechnology
  • Precision Biologics
  • Progenics Pharmaceuticals
  • Prolong Pharmaceuticals
  • Promedior
  • ProMetic Biotherapeutics
  • ProNAi Therapeutics
  • ProQR Therapeutics
  • Protalex
  • Provectus Pharmaceuticals
  • PTC Therapeutics
  • QLT
  • Quest PharmaTech
  • Qurient
  • Raptor Pharmaceutical
  • Rebiotx
  • Regeneron Pharmaceuticals
  • Regulus Therapeutics & Sanofi US
  • Retrophin
  • RetroSense Therapeutics
  • ReveraGen Biopharma
  • Rexahn Pharmaceuticals
  • Rhythm Metabolics
  • Rigel Pharmaceuticals
  • River Vision
  • Roche
  • Sanofi S. A.
  • Santhera Pharmaceuticals
  • Sarepta Therapeutics
  • Savara Pharmaceuticals
  • Seattle Genetics
  • Selexys Pharmaceuticals
  • SELLAS Life Sciences
  • Sequella
  • Seres Health
  • Shire plc
  • SIGA Technologies
  • Sigma-Tau Pharmaceuticals
  • SillaJen Biotherapeutics
  • Soligenix
  • Soricimed Biopharma
  • Spark Therapeutics
  • StemcentRx
  • Stemline Therapeutics
  • Sun BioPharma
  • Sun Pharmaceuticals
  • Sunesis Pharmaceuticals
  • Takeda Pharmaceuticals
  • Tapimmune
  • Tarix Orphan
  • TESARO
  • TetraLogic Pharmaceuticals
  • Teva Pharmaceutical
  • TG Therapeutics
  • Tiziana Life Sciences
  • Tocagen
  • Tolero Pharmaceuticals
  • Tracon Pharmaceuticals
  • TransDerm
  • Triphase Research & Development
  • Triphase Research and Development
  • Ultragenyx Pharmaceutical
  • Ultragenyx Pharmaceutical
  • uniQure
  • UroGen
  • Vascular Biogenics
  • VentiRx Pharmaceuticals
  • Verastem
  • Vertex Pharmaceuticals
  • Viamet Pharmaceuticals
  • Vicus Therapeutics
  • Viralytics
  • Viventia Biotech
  • VivoLux
  • Vtesse
  • Wilson Therapeutics
  • Xeris Pharmaceuticals
  • XOMA
  • Ziopharm Oncology
  • Zogenix
  • Zywie